Title
Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey
Date Issued
01 January 2009
Access level
open access
Resource Type
journal article
Author(s)
Sousa R.M.
Ferri C.P.
Acosta D.
Albanese E.
Huang Y.
Jacob K.S.
Jotheeswaran A.T.
Rodriguez J.J.L.
Pichardo G.R.
Rodriguez M.C.
Salas A.
Sosa A.L.
Williams J.
Zuniga T.
Prince M.
Publisher(s)
Elsevier B.V.
Abstract
Background: Disability in elderly people in countries with low and middle incomes is little studied; according to Global Burden of Disease estimates, visual impairment is the leading contributor to years lived with disability in this population. We aimed to assess the contribution of physical, mental, and cognitive chronic diseases to disability, and the extent to which sociodemographic and health characteristics account for geographical variation in disability. Methods: We undertook cross-sectional surveys of residents aged older than 65 years (n=15 022) in 11 sites in seven countries with low and middle incomes (China, India, Cuba, Dominican Republic, Venezuela, Mexico, and Peru). Disability was assessed with the 12-item WHO disability assessment schedule 2.0. Dementia, depression, hypertension, and chronic obstructive pulmonary disease were ascertained by clinical assessment; diabetes, stroke, and heart disease by self-reported diagnosis; and sensory, gastrointestinal, skin, limb, and arthritic disorders by self-reported impairment. Independent contributions to disability scores were assessed by zero-inflated negative binomial regression and Poisson regression to generate population-attributable prevalence fractions (PAPF). Findings: In regions other than rural India and Venezuela, dementia made the largest contribution to disability (median PAPF 25·1% [IQR 19·2-43·6]). Other substantial contributors were stroke (11·4% [1·8-21·4]), limb impairment (10·5% [5·7-33·8]), arthritis (9·9% [3·2-34·8]), depression (8·3% [0·5-23·0]), eyesight problems (6·8% [1·7-17·6]), and gastrointestinal impairments (6·5% [0·3-23·1]). Associations with chronic diseases accounted for around two-thirds of prevalent disability. When zero inflation was taken into account, between-site differences in disability scores were largely attributable to compositional differences in health and sociodemographic characteristics. Interpretation: On the basis of empirical research, dementia, not blindness, is overwhelmingly the most important independent contributor to disability for elderly people in countries with low and middle incomes. Chronic diseases of the brain and mind deserve increased prioritisation. Besides disability, they lead to dependency and present stressful, complex, long-term challenges to carers. Societal costs are enormous. Funding: Wellcome Trust; WHO; US Alzheimer's Association; Fondo Nacional de Ciencia Y Tecnologia, Consejo de Desarrollo Cientifico Y Humanistico, Universidad Central de Venezuela. © 2009 Elsevier Ltd. All rights reserved.
Start page
1821
End page
1830
Volume
374
Issue
9704
Language
English
OCDE Knowledge area
Psiquiatría
Scopus EID
2-s2.0-71549118783
PubMed ID
Source
The Lancet
ISSN of the container
01406736
Sponsor(s)
The 10/66 Dementia Research Group population-based surveys were funded by: the Wellcome Trust (UK) ( GR066133 ); WHO; the US Alzheimer's Association ( IIRG–04–1286 ); and the Fondo Nacional de Ciencia Y Tecnologia, Consejo de Desarrollo Cientifico Y Humanistico, Universidad Central de Venezuela (Venezuela). The Rockefeller Foundation supported our dissemination meeting in their Bellagio Centre. Alzheimer's Disease International (ADI) has provided support for networking and infrastructure. The 10/66 Dementia Research Group works closely with ADI, which is a non-profit federation of 77 Alzheimer associations around the world. ADI is committed to strengthening Alzheimer associations worldwide, raising awareness regarding dementia and Alzheimer's disease, and advocating for more and better services for people with dementia and their caregivers. ADI is supported in part by grants from GlaxoSmithKline, Novartis, Lundbeck, Pfizer, and Eisai.
Sources of information: Directorio de Producción Científica Scopus